Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Clinical trial NCT06567743 · RECRUITING
Trial details
- NCT number
- NCT06567743
- Sponsor
- CG Oncology, Inc.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-09-16
- Primary completion
- 2027-03-31
- Enrollment
- 325
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.